SCTbio

SCTbio is a specialized CDMO focused on the high-growth cell and gene therapy sector, offering end-to-end manufacturing and development services. Its core expertise lies in cell-based therapeutics, including dendritic cell therapies and CAR-T constructs, as well as lentiviral and gammaretroviral vector production. Supported by the PPF Group, the company differentiates itself through a client-centric approach and a unique global network of over 150 apheresis collection centers, positioning it as a strategic partner for biotechs advancing novel therapies to the clinic.

Integrated CDMO services for cell and gene therapies, specializing in cGMP manufacturing of cell-based products (dendritic cells, CAR-T) and retroviral vectors (lentiviral, gammaretroviral), supported by a global apheresis collection network.

SCTbio competes in a crowded CDMO space, facing large, diversified players (e.g., Lonza, Catalent, Thermo Fisher) and other specialized CGT CDMOs. It differentiates through deep specialization in cell/retroviral vector therapy, a client-focused service model, and its proprietary network of apheresis centers, targeting small to mid-sized biotechs.